{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sodium+Glucose+Co-transporter+2+%28SGLT2%29+Inhibitor",
    "query": {
      "intervention": "Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 19,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sodium+Glucose+Co-transporter+2+%28SGLT2%29+Inhibitor&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T01:22:43.114Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05614115",
      "title": "Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End-stage Kidney Disease",
        "Kidney Disease, Chronic",
        "Dialysis",
        "Diabetic",
        "Non-diabetic",
        "Kidney Dysfunction",
        "Kidney Failure",
        "Hemodialysis"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2023-03-21",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-10-10T01:22:43.114Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05614115"
    },
    {
      "nct_id": "NCT03173963",
      "title": "Empaglifozin in Early Diabetic Kidney Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetic Kidney Disease",
        "Diabetes Mellitus Type 2"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 0,
      "start_date": "2017-05-27",
      "completion_date": "2020-02-21",
      "has_results": false,
      "last_update_posted_date": "2020-02-25",
      "last_synced_at": "2026-10-10T01:22:43.114Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03173963"
    },
    {
      "nct_id": "NCT00963768",
      "title": "A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "JNJ 28431754",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "25 Years to 65 Years"
      },
      "enrollment_count": 116,
      "start_date": "2007-06",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2014-04-23",
      "last_synced_at": "2026-10-10T01:22:43.114Z",
      "location_count": 1,
      "location_summary": "Chula Vista, California",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00963768"
    },
    {
      "nct_id": "NCT04201496",
      "title": "SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "No Empagliflozin + Control-IQ x 4 wks then Basal-IQ x 2 wks",
          "type": "DEVICE"
        },
        {
          "name": "No Empagliflozin + Basal-IQ x 2 wks then Control-IQ x 4 wks",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DEVICE"
      ],
      "sponsor": "Ananda Basu, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 34,
      "start_date": "2020-02-24",
      "completion_date": "2021-09-07",
      "has_results": false,
      "last_update_posted_date": "2022-08-11",
      "last_synced_at": "2026-10-10T01:22:43.114Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04201496"
    },
    {
      "nct_id": "NCT02404870",
      "title": "Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Canagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2014-09-16",
      "completion_date": "2019-09-03",
      "has_results": false,
      "last_update_posted_date": "2025-03-04",
      "last_synced_at": "2026-10-10T01:22:43.114Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02404870"
    },
    {
      "nct_id": "NCT03169959",
      "title": "A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "2.5 mg Saxagliptin tablet",
          "type": "DRUG"
        },
        {
          "name": "5 mg dapagliflozin / 1000 mg metformin XR tablet",
          "type": "DRUG"
        },
        {
          "name": "Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR",
          "type": "DRUG"
        },
        {
          "name": "5 mg saxagliptin",
          "type": "DRUG"
        },
        {
          "name": "10 mg dapagliflozin / 1000 mg metformin XR tablet",
          "type": "DRUG"
        },
        {
          "name": "Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 85,
      "start_date": "2017-05-29",
      "completion_date": "2017-08-03",
      "has_results": false,
      "last_update_posted_date": "2017-08-14",
      "last_synced_at": "2026-10-10T01:22:43.114Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03169959"
    },
    {
      "nct_id": "NCT05305911",
      "title": "Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Attack",
        "Enlarged Heart"
      ],
      "interventions": [
        {
          "name": "SGLT-2 inhibitors",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Minneapolis Heart Institute Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 81,
      "start_date": "2022-08-03",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2024-10-08",
      "last_synced_at": "2026-10-10T01:22:43.114Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05305911"
    },
    {
      "nct_id": "NCT03970044",
      "title": "Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Exenatide 2 MG",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin 10 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Consano Clinical Research, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 67,
      "start_date": "2019-07-02",
      "completion_date": "2021-06-01",
      "has_results": false,
      "last_update_posted_date": "2021-08-30",
      "last_synced_at": "2026-10-10T01:22:43.114Z",
      "location_count": 1,
      "location_summary": "Shavano Park, Texas",
      "locations": [
        {
          "city": "Shavano Park",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03970044"
    },
    {
      "nct_id": "NCT06609356",
      "title": "Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus",
        "Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY)",
        "MODY2 Diabetes",
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "Study Visit 1",
          "type": "PROCEDURE"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Study Visit 2",
          "type": "PROCEDURE"
        },
        {
          "name": "Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 27,
      "start_date": "2025-07-03",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-23",
      "last_synced_at": "2026-10-10T01:22:43.114Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06609356"
    },
    {
      "nct_id": "NCT05570305",
      "title": "Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "Zibotentan",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin and Zibotentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University Medical Center Groningen",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 42,
      "start_date": "2022-10-06",
      "completion_date": "2025-03-05",
      "has_results": false,
      "last_update_posted_date": "2025-04-30",
      "last_synced_at": "2026-10-10T01:22:43.114Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05570305"
    }
  ]
}